• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » ASKA Research Partners with Japanese CRO

ASKA Research Partners with Japanese CRO

November 3, 2008
CenterWatch Staff

ASKA Research, a contract research organization (CRO) based in Vancouver, Canada, is expanding its clinical trial services into Japan through a strategic partnership with Japanese CRO Asklep.

The partnership with ASKLEP will allow ASKA to create a presence in Japan while helping ASKLEP advance in North America. ASKLEP, which is expanding into other parts of Asia, will do all the on-the-ground work in Japan and Asia while ASKA manages North America.

“If we’re requested to submit a proposal on a global trial that involves Asia, we’ll ask our partner ASKLEP to participate with us. We are the primary CRO, and they become the CRO that is working with us in partnership, and vice versa. We expect that we’ll be able to bring clinical trials to each other,” said ASKA CEO and founder Valerie Willetts.

ASKA provides clinical trial management services to pharmaceutical companies throughout Canada, the United States and now Japan through a network of more than 200 regionally located clinical research professionals.

Clinical trial sites in Japan are underutilized, according to Willetts, and expanding to Asia has been a strategic goal for the company since ASKA was founded in 1995. Even ASKA’s name is of Japanese origin, meaning “new development,” Willetts said.

ASKA and ASKLEP executives first began discussing a strategic partnership at the DIA Annual Meeting in Boston earlier this year. The two CROs are still finalizing the details of the partnership, but Willetts hopes to have the joint alliance operating by early next year.

“We have great synergy among our team members and thought that it would be a very productive alliance to bring clinical trials to each other across the ocean,” Willetts said. “We’re working out a joint operating plan where we’re identifying a number of projects per year. We haven’t set our target yet, but, of course, it’s always the most we possibly can. This alliance allows us to be able to market ourselves as a global organization to potential clients and that’s very well-received.”

This is the third partnership of its kind for ASKA, which has similar agreements with Harrison Clinical Research Group in Munich, Germany, and CTI Clinical Trial and Consulting Services in Cincinnati, Ohio.

ASKA is also working on structuring an alliance with a CRO in Australia and New Zealand and looking for partners in India and in South America, Willetts said.

“We’re just testing the waters with a group in India. Before we sign any agreements, we like to test the waters and work together on a clinical trial. So far it’s looking very promising,” she said.

ASKA plans to expand its internal team from six to eight full-time employees next year, and, in the future, the company may grow through acquisitions as well as partnerships, Willetts said.

“It’s an interesting time for ASKA and certainly we’ve begun to entertain that notion,” she said.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing